Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2022-03-03 Director's Dealing
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2022-03-03 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated March 1, 2022, reporting the appointment of a new independent director to the company's Board of Directors. The content focuses on management changes, including compensation and indemnification agreements related to the new director. There are no financial statements or detailed financial data presented. The primary subject is the change in board composition and related management information. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4178 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to clear and explicit content about director appointment and no conflicting information.
2022-03-01 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 15, 2022. It includes a reference to an attached investor presentation (Exhibit 99.1) used for discussions with investors. The text explicitly states that the presentation is being furnished and is not filed for regulatory purposes. The content focuses on the disclosure of an investor presentation rather than detailed financial statements or management discussion. The document length is 3425 characters, which is relatively short and consistent with a regulatory filing announcing an investor presentation rather than the presentation itself. Therefore, the document is best classified as an Investor Presentation (IP).
2022-02-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 14, 2022. It announces preliminary clinical trial results and includes a press release as an exhibit. The text explicitly states that the information is being furnished and not filed, and it is a short document (3936 characters) primarily serving as a disclosure of a press release. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain a full report or detailed financial data. The document is not an earnings release, annual report, or any other specific report type but a current report disclosing material information.
2022-02-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text indicates it is a press release about an updated independent safety review related to clinical trials, attached as Exhibit 99.1. The document explicitly states that the information is being furnished and not filed, and it is a short report (3828 characters). There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. The document is not a full report but a current report filing with a press release attached, so it is best classified as Regulatory Filings (RNS).
2022-01-18 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 10, 2022. It includes an Item 7.01 Regulation FD Disclosure about an investor webinar and references an Exhibit 99.1 which is an Investor Presentation. The text explicitly states that the information is being furnished and not filed, and the main content is an investor presentation. The document length is 3400 characters, which is relatively short and consistent with a report announcing or furnishing an investor presentation rather than a full financial report. Therefore, the document is best classified as an Investor Presentation (IP).
2022-01-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.